Zydus Lifesciences Limited Stock Price Today (NSE: ZYDUSLIFE)
Fundamental Score
Zydus Lifesciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zydus Lifesciences Limited share price today is ₹1135.00, up +1.58% on NSE/BSE as of 22 October 2026. Zydus Lifesciences Limited (ZYDUSLIFE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.13L (Cr). The 52-week high for ZYDUSLIFE share price is ₹1232.10 and the 52-week low is ₹835.50. At a P/E ratio of 25.30x, ZYDUSLIFE is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.74% and a debt-to-equity ratio of 0.43.
Zydus Lifesciences Limited Share Price Chart — NSE/BSE Historical Performance
Zydus Lifesciences Limited share price chart: 1.40% return over the past month. 52-week high ₹1232.10, 52-week low ₹835.50.
Zydus Lifesciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1116.00 | ₹1138.50 | ₹1100.30 | ₹1135.00 | 13.58L (Cr) | |
| ₹1113.70 | ₹1126.90 | ₹1106.00 | ₹1117.30 | 7.47L (Cr) | |
| ₹1116.40 | ₹1134.20 | ₹1110.30 | ₹1113.90 | 2.53L (Cr) | |
| ₹1140.10 | ₹1146.50 | ₹1123.00 | ₹1123.00 | 15.99L (Cr) | |
| ₹1121.00 | ₹1150.80 | ₹1114.70 | ₹1140.20 | 11.28L (Cr) | |
| ₹1125.00 | ₹1150.90 | ₹1108.00 | ₹1124.70 | 23.34L (Cr) | |
| ₹1136.10 | ₹1139.80 | ₹1112.30 | ₹1132.50 | 11.14L (Cr) | |
| ₹1117.20 | ₹1139.50 | ₹1107.30 | ₹1134.40 | 7.90L (Cr) | |
| ₹1112.00 | ₹1123.70 | ₹1105.40 | ₹1117.50 | 5.30L (Cr) | |
| ₹1165.00 | ₹1166.90 | ₹1109.10 | ₹1112.00 | 17.46L (Cr) |
Zydus Lifesciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1151.00 | ₹1167.40 | ₹1100.30 | ₹1135.00 | -1.39% | |
| ₹1167.30 | ₹1232.10 | ₹1086.00 | ₹1162.00 | -0.45% | |
| ₹1135.00 | ₹1198.90 | ₹1092.60 | ₹1161.30 | +2.32% | |
| ₹1081.00 | ₹1108.90 | ₹1061.10 | ₹1078.30 | -0.25% | |
| ₹895.00 | ₹1115.50 | ₹893.15 | ₹1077.70 | +20.41% | |
| ₹888.00 | ₹962.90 | ₹835.50 | ₹891.90 | +0.44% | |
| ₹893.65 | ₹936.15 | ₹858.00 | ₹871.20 | -2.51% | |
| ₹876.30 | ₹947.55 | ₹863.65 | ₹921.70 | +5.18% | |
| ₹919.80 | ₹941.00 | ₹855.95 | ₹885.30 | -3.75% | |
| ₹942.10 | ₹947.00 | ₹896.75 | ₹914.35 | -2.95% | |
| ₹970.50 | ₹998.00 | ₹920.50 | ₹942.50 | -2.89% | |
| ₹1013.95 | ₹1017.15 | ₹973.50 | ₹974.45 | -3.90% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zydus Lifesciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zydus Lifesciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZYDUSLIFE across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (19.74%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.77%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.27%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 25.30 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (21.96%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (19.17% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.76% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (16.09x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹8636.20 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Profit Decline Concern (-35.93%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Zydus Lifesciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Zydus Lifesciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Zydus Lifesciences LimitedZydus Lifescien...Selected✓ ZYDUSLIFE • 532321 | 71.6/100 | ₹1135.00₹1135 | ₹113273.00₹113273.00 | 25.30Average 25.3 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Glenmark Pharmaceuticals LimitedGlenmark Pharma... GLENMARK • 532296 | 63.9/100 | ₹2226.70₹2227 | ₹62837.47₹62837.47 | 34.95Average 35.0 Average | 0.00%Poor 0.00% Poor | 18.58%Good 18.58% Good | 0.00Excellent 0.0 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Laurus Labs Limited share price111296.90 Cr
- Cipla Limited share price107048.20 Cr
Zydus Lifesciences Limited PE Ratio History
Historical price-to-earnings ratio for ZYDUSLIFE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹44.97 | ₹914.35 | 20.3x |
| FY 2024 | ₹38.14 | ₹971.70 | 25.5x |
| FY 2023 | ₹19.30 | ₹689.20 | 35.7x |
| FY 2022 | ₹43.83 | ₹419.95 | 9.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zydus Lifesciences Limited Dividend History
Annual cash dividends paid by ZYDUSLIFE — dividend yield 0.09%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹302.50 Cr |
| FY 2024 | ₹621.00 Cr |
| FY 2023 | ₹267.10 Cr |
| FY 2022 | ₹372.20 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Zydus Lifesciences Limited Quarterly Performance
Latest quarterly metrics for ZYDUSLIFE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
21.96%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-35.93%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.45%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.76%
Compounded annual net profit growth over 5 years
Zydus Lifesciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZYDUSLIFE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Zydus Lifesciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Zydus Lifesciences Limited (ZYDUSLIFE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Zydus Lifesciences Limited
About ZYDUSLIFE (Zydus Lifesciences Limited)
Zydus Lifesciences Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing global health. The company meticulously researches..., develops, manufactures, and distributes a wide spectrum of pharmaceutical products catering to diverse therapeutic areas. With a strong presence in India, the United States, and numerous international markets, Zydus Lifesciences is dedicated to addressing unmet medical needs and improving patient outcomes worldwide. Their infrastructure supports end-to-end pharmaceutical solutions, from drug discovery to commercialization, ensuring quality and accessibility across its product range. They are constantly striving to improve health outcomes and the quality of life across the globe. The organization operates through distinct divisions focused on Pharmaceuticals, which are its central activity. They make active pharmaceutical ingredients, finished formulas for doses, generics, biosimilars, novel products, and specialty products. It also has a division dedicated to Consumer Products. This dual focus allows Zydus Lifesciences to leverage its scientific expertise to create both prescription medications and over-the-counter healthcare solutions. The company's dedication to research and development is evident in its consistent introduction of innovative products and therapies. Zydus Lifesciences distinguishes itself through its dedication to quality, safety, and affordability, making it a trusted partner in healthcare. Zydus Lifesciences extends its reach beyond prescription medications through a well-established portfolio of well-known consumer brands. These include brands in personal care, food and nutrition, and everyday health. These product lines, which include personal care products, nutritional supplements, and wellness goods, reflect the company's comprehensive approach to health and well-being. They are dedicated to providing accessible and high-quality options to consumers. Through this multi-pronged strategy, Zydus Lifesciences continues to expand its footprint in the healthcare industry, further solidifying its position as a leading and responsible global healthcare provider.
Company Details
Key Leadership
ZYDUSLIFE Share Price: Frequently Asked Questions
What is the current share price of Zydus Lifesciences Limited?
Zydus Lifesciences Limited (ZYDUSLIFE) trades at ₹1135.00 on NSE and BSE. Market cap ₹1.13L (Cr). Educational data only.
What is the P/E ratio of Zydus Lifesciences Limited?
Zydus Lifesciences Limited has a P/E of 25.30x vs industry average 34.89x.
What is the Bull Run score for Zydus Lifesciences Limited?
Zydus Lifesciences Limited has a Bull Run score of 71.6/100 based on 25+ financial parameters.
Does Zydus Lifesciences Limited pay dividends?
Zydus Lifesciences Limited has a dividend yield of 0.09%. Past dividends don't guarantee future payments.
What is the ROE of Zydus Lifesciences Limited?
Zydus Lifesciences Limited has ROE of 19.74%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zydus Lifesciences Limited?
Zydus Lifesciences Limited has debt-to-equity of 0.43.
Is Zydus Lifesciences Limited a good investment?
Bull Run gives Zydus Lifesciences Limited a score of 71.6/100. This is not investment advice — consult a SEBI-registered advisor.